1. Emdin M, Vittorini S, Passino C, Clerico A. Old and new biomarkers of heart failure. Eur J Heart Fail. 2009; 11(4):331–335. PMID:
19329823.
Article
2. Khanam SS, Choi E, Son JW, Lee JW, Youn YJ, Yoon J, et al. Validation of the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) heart failure risk score and the effect of adding natriuretic peptide for predicting mortality after discharge in hospitalized patients with heart failure. PLoS One. 2018; 13(11):e0206380. PMID:
30485284.
Article
3. Lee JH, Kim MS, Kim EJ, Park DG, Cho HJ, Yoo BS, et al. KSHF guidelines for the management of acute heart failure: Part I. Definition, epidemiology and diagnosis of acute heart failure. Korean Circ J. 2019; 49(1):1–21. PMID:
30637993.
Article
4. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008; 358(20):2148–2159. PMID:
18480207.
Article
5. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007; 369(9568):1208–1219. PMID:
17416265.
Article
6. Laragh JH. The renin system and future trends in management of high blood pressure. Clin Exp Hypertens. 1980; 2(3-4):525–552. PMID:
6253242.
Article
7. Laragh JH, Sealey JE. Abnormal sodium metabolism and plasma renin activity (renal renin secretion) and the vasoconstriction volume hypothesis: implications for pathogenesis and treatment of hypertension and its vascular consequences (heart attack, stroke). Clin Chem. 1991; 37(10 Pt 2):1820–1827. PMID:
1914196.
Article
8. Brunner HR, Gavras H, Laragh JH. Specific inhibition of the renin-angiotensin system: a key to understanding blood pressure regulation. Prog Cardiovasc Dis. 1974; 17(2):87–98. PMID:
4369198.
Article
9. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972; 286(9):441–449. PMID:
4257928.
Article
10. Brunner HR, Sealey JE, Laragh JH. Renin as a risk factor in essential hypertension: more evidence. Am J Med. 1973; 55(3):295–302. PMID:
4746557.
Article
11. Jang SY, Chae SC, Bae MH, Lee JH, Yang DH, Park HS, et al. Effect of renin-angiotensin system blockade in patients with severe renal insufficiency and heart failure. Int J Cardiol. 2018; 266:180–186. PMID:
29887444.
Article
12. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004; 25(4):292–299. PMID:
14984917.
Article
13. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15(4):361–387. PMID:
8668867.
Article
14. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44(3):837–845. PMID:
3203132.
Article
15. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27(2):157–172. PMID:
17569110.
Article
16. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990; 82(5):1730–1736. PMID:
2225374.
17. Packer M. Pathophysiology of chronic heart failure. Lancet. 1992; 340(8811):88–92. PMID:
1352022.
Article
18. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993; 87(6):Suppl. VI40–VI48. PMID:
8500238.
19. Benedict CR, Johnstone DE, Weiner DH, Bourassa MG, Bittner V, Kay R, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1994; 23(6):1410–1420. PMID:
7909822.
Article
20. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 1982; 49(7):1659–1666. PMID:
7044086.
Article
21. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991; 87(4):1402–1412. PMID:
1849149.
Article
22. Rachwan RJ, Butler J, Collins SP, Cotter G, Davison BA, Senger S, et al. Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. Eur J Heart Fail. 2019; 21(12):1561–1570. PMID:
31646707.
Article
23. Nijst P, Verbrugge FH, Martens P, Bertrand PB, Dupont M, Francis GS, et al. Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy. J Renin Angiotensin Aldosterone Syst. 2017; 18(3):1470320317729919. PMID:
28875746.
Article
24. Ueda T, Kawakami R, Nishida T, Onoue K, Soeda T, Okayama S, et al. Plasma renin activity is a strong and independent prognostic indicator in patients with acute decompensated heart failure treated with renin-angiotensin system inhibitors. Circ J. 2015; 79(6):1307–1314. PMID:
25753468.
Article